HONG KONG – For the past several years, biopharma firms around the globe have been urged to develop a strategy for moving into China, and with good reason. China's pharmaceutical market value is expected to grow from $123 billion in 2017 to $160 billion by 2022, according to management consulting firm L.E.K. Consulting.
TAIPEI, Taiwan – Relatively strong flows of capital and partnerships with global players are helping Asia's biotech sector boom, said speakers at the Asia Pacific Biotech Investment Forum last week.
HONG KONG – For the past several years, biopharma firms around the globe have been urged to develop a strategy for moving into China, and with good reason. China's pharmaceutical market value is expected to grow from $123 billion in 2017 to $160 billion by 2022, according to management consulting firm L.E.K. Consulting.
TAIPEI, Taiwan – How to attract capital is a well-trod theme in the biopharma sector, but the best investors bring more than just money to the table, speakers noted during the Asia Pacific Biotech Investment Forum this week. The right kind of business know-how could help turn a company with a good idea and solid research into a unicorn, a startup with a valuation of $1 billion.
TAIPEI, Taiwan – Relatively strong flows of capital and partnerships with global players are helping Asia's biotech sector boom, said speakers at the Asia Pacific Biotech Investment Forum on Wednesday.
HONG KONG – Clinical-stage biopharma Taiwanj Pharmaceuticals Co. Ltd. said its drug candidate, JKB-122, for treating nonalcoholic fatty liver disease (NAFLD) showed positive results in a 12-week phase II study in Taiwan. Encouraged by those positive results, the company already has plans to push the compound to the next clinical stage in its homeland, with an IND expected to be filed in the second quarter of next year.
HONG KONG – Clinical-stage biopharma Taiwanj Pharmaceuticals Co. Ltd. said its drug candidate, JKB-122, for treating nonalcoholic fatty liver disease (NAFLD) showed positive results in a 12-week phase II study in Taiwan. Encouraged by those positive results, the company already has plans to push the compound to the next clinical stage in its homeland, with an IND expected to be filed in the second quarter of next year.
HONG KONG – Denovo Biopharma LLC, a cross-border biotech registered in San Diego and Hangzhou, China, has been granted IND approval by Chinese regulators to conduct international multicenter clinical trials for its neuroscience drug, DB-103 (pomaglumetad). If successful, DB-103 could prove a heavyweight product in the schizophrenia space.
HONG KONG – Denovo Biopharma LLC, a cross-border biotech registered in San Diego and Hangzhou, China, has been granted IND approval by Chinese regulators to conduct international multicenter clinical trials for its neuroscience drug, DB-103 (pomaglumetad). If successful, DB-103 could prove a heavyweight product in the schizophrenia space.
